Avara’s Liscate facility provides sterile manufacturing, fill-finish, and packaging services for supply to European, United States, Canadian, and Latin American markets.  During Q4 2019, the facility hosted the US FDA as part of a Pre-Approval Inspection for a new Client’s product to be manufactured in the Small Volume Parenterals department.  In addition, a routine GMP inspection for the Lyophilization department was conducted.  We were delighted that the US FDA Inspector has acknowledged the high standards and experience in Avara Liscate by recommending the renewal of the license and approval of the new product. Along with approvals also received for AIFA, ANVISA and MFDS Korea, this completes a successful year of regulatory inspections for Avara Liscate. 

Also, Avara Liscate is excited to announce the appointment of a new Manufacturing Director to the leadership team.  Vincenzo Riello joins the Avara Liscate team on January 7th, 2020 and brings with him a wealth of experience in sterile manufacturing gained over many years in large pharma organizations as well as CDMOs.  Marco Scanziani, who held the position prior, will be Avara Liscate’s new Customer Relationship Leader and will apply his 15 years of manufacturing and quality experience to leading the Project Management function in Avara Liscate.

Avara Liscate, and indeed the whole Avara group, is excited to welcome the New Year and decade and look forward to continuing to support and collaborate with our existing and new Clients.